PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Genetic and immunologic susceptibility to statin-related myopathy.

Myopathy with statin-fibrate combination therapy: clinical considerations - Document - Gale OneFile: Health and Medicine

Statin Myopathy.pdf

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

JCM, Free Full-Text

The Role of Coenzyme Q10 in Statin-Associated Myopathy: A Systematic Review

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference - Canadian Journal of Cardiology

2018 Guidelines for the management of dyslipidemia

Hypertriglyceridemia: Practice Essentials, Pathophysiology, Etiology

Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease

Statin Myopathy.pdf

2018 Guidelines for the management of dyslipidemia

Frontiers Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis